Wegovy and Ozempic alternatives: what the evidence actually shows

Why Ozempic is not actually a weight-loss alternative in the UK

This is the most common point of confusion around this topic. Ozempic and Wegovy both contain semaglutide, but they hold separate UK licences. Ozempic is authorised by the MHRA for type 2 diabetes management; Wegovy is authorised for weight management in adults with a BMI of 30 or above, or 27 and above where a weight-related condition is present. Prescribing Ozempic for weight loss would be an off-label use, legal for a clinician to choose in the right circumstances, but not what it was approved for, and not something a legitimate regulated pharmacy would supply for that purpose without proper documentation.

If a website tells you Ozempic is a weight-loss drug you can order for slimming, treat that as a red flag. Our explainer on whether Wegovy and Ozempic are the same thing goes into this in more detail, including why the two products carry different dosing schedules despite the shared active ingredient. The MHRA has been clear that GLP-1 medicines are not assessed or approved for cosmetic weight loss, and that buying these medicines from unverified sources (particularly online sellers operating without proper clinical oversight) carries real safety risks, including the risk of semaglutide overdose where dosing is not properly supervised.

So when someone searches for an alternative to semaglutide or a Wegovy alternative, what they usually mean is: are there other licensed medicines that work differently and might suit me better?

What tirzepatide adds, and what the SURMOUNT-5 trial showed

Tirzepatide, sold in the UK as Mounjaro, is the most significant semaglutide alternative licensed for weight management in Britain. Where semaglutide activates only the GLP-1 receptor, tirzepatide activates two: GLP-1 and GIP. That dual action affects appetite signalling and gastric emptying through complementary pathways, which is reflected in the trial outcomes. In SURMOUNT-1, involving 2,539 adults with obesity, participants on 15mg tirzepatide lost an average of around 20–21% of body weight over 72 weeks, as reported in the New England Journal of Medicine.

The more telling comparison came in SURMOUNT-5, the first direct head-to-head trial of tirzepatide against semaglutide 2.4mg. Over 72 weeks in 751 adults with obesity and no diabetes, tirzepatide produced greater average weight loss than the maximum licensed semaglutide injection dose. NICE referenced this indirect and direct comparative evidence when recommending tirzepatide in Technology Appraisal TA1026, published in December 2024 and updated in September 2025.

That said, greater average trial weight loss does not automatically mean tirzepatide is the right medicine for any given person. Side-effect profiles differ between individuals, medical histories shape which medicine a prescriber will recommend, and some people do very well on semaglutide. The full profile of semaglutide as a weight-loss treatment covers its evidence base alongside those individual considerations.

Wegovy 7.2mg: a higher-dose semaglutide option that narrows the gap

It is worth knowing that semaglutide itself has moved on. The MHRA approved a 7.2mg maintenance dose of Wegovy on 12 January 2026, and on 14 April 2026 approved a dedicated single-dose 7.2mg pen, one weekly injection at a preset dose, with a built-in covered needle that locks after use. Trials at this higher dose reported average weight loss of around 20.7% over 72 weeks, which narrows the gap considerably compared with the 2.4mg dose studied in STEP 1. This is relevant context for anyone weighing up a semaglutide alternative: the Wegovy option is not static, and the Wegovy treatment page has the current detail.

The NHS England guidance on weight-management injections outlines what the NHS currently offers, the eligibility criteria that apply on the NHS, and the clinical support that should accompany any prescription. Private access through a GPhC-registered pharmacy operates under the same prescribing standards but without the same waiting-list constraints, though eligibility is still individually assessed by a prescriber.

What about over-the-counter or non-prescription alternatives?

Orlistat is the one weight-loss medicine available without a prescription in some formulations, specifically the 60mg capsule (branded as Alli), which is a pharmacy medicine. The prescription-strength version (120mg) requires a GP or independent prescriber. Orlistat works by blocking absorption of around a third of dietary fat rather than acting on appetite signalling, so it is a different category of treatment. Results in clinical trials are more modest than those seen with GLP-1 medicines. Our page on over-the-counter Wegovy alternatives explains how orlistat compares and who it tends to suit.

There is no licensed over-the-counter equivalent to Wegovy or Mounjaro. Any product marketed as such, particularly via social media, should be treated with scepticism. In October 2025 the MHRA raided the first illicit UK site manufacturing fake tirzepatide pens, and enforcement in 2025 accounted for roughly 20 million doses of illegally traded weight-loss medicines at an estimated street value of £45 million. Fake pens have previously been found to contain insulin, with serious consequences for the people who used them. If you want to explore what private weight-loss treatment with a licensed medicine looks like (including what arrives (a tracked DPD parcel, plain packaging, your pen inside) and what the clinical process involves) our treatment options page sets it out plainly. For anyone considering costs across providers, the Wegovy price comparison page is a useful starting point.